Seroprevalence of Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Among People Who Use Drugs in Turkey - Takeaways - MDSpire

Seroprevalence of Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Among People Who Use Drugs in Turkey

  • By

  • Ali Asan

  • Cetin Turan

  • Omer Senormanci

  • Merve Sefa Sayar

  • Salih Metin

  • Ismail Necati Hakyemez

  • March 13, 2025

  • 0 min

Share

  • 1

    The study analyzed 8071 patients at a treatment center in Turkey to assess the prevalence of HIV, HBV, and HCV among drug users.

  • 2

    The positivity rates for HBsAg, anti-HBs, anti-HCV, and anti-HIV were found to be 2.2%, 33.2%, 0.8%, and 0.6%, respectively.

  • 3

    In the people who inject drugs (PWID) group, seropositivity rates for HBsAg, anti-HCV, and anti-HIV were significantly higher than in non-injection drug users.

  • 4

    The study highlighted the importance of raising awareness among individuals with these infections to prevent severe health outcomes and transmission.

  • 5

    The findings indicate that HBV and HCV prevalence among drug users is similar to that in the general population, emphasizing the need for targeted interventions.

Original Source(s)

Seroprevalence of Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Among People Who Use Drugs in Turkey

  • by Ali Asan, Cetin Turan, Omer Senormanci, Merve Sefa Sayar, Salih Metin, Ismail Necati Hakyemez

  • March 13, 2025

Related Content

Assessment of the occurrence and factors influencing hepatitis B, hepatitis C, and liver damage in individuals with HIV undergoing antiretroviral treatment in Ghana's Upper East Region

At the Hart of Pathology

Sitting Down With... John Hart, Professor and Vice Chair of Anatomic Pathology at the University of Chicago Medicine

Low Follow-Up After Behavioral ED Care

Follow-up occurred after fewer than 15% of mental health ED visits and about 11% of substance use–related visits in Washington Medicaid claims.